Table 4.
Frequency of positive responses and odds ratios for candidate items in the Madrid cohort.
| Criterion | Scleroderma N = 175 |
Non-SSc comparisons | Combined Non-SSc comparisons |
OR | ||
|---|---|---|---|---|---|---|
| SLE N = 223 |
Myositisa N = 53 |
Raynaud’s Disease N = 135 |
N = 411 | |||
| Abnormal nailfold capillary pattern | 113/137 (83%) | NA | NA | 3 (2%) | 3/135 | NAb |
| Anti-centromere antibody | 45/167 (27%) | 3/203 (2%) | 1 (2%) | 1 (1%) | 5/391 | 28 |
| Anti-topoisomerase-I antibody | 59/167 (35%) | 2/103 (1%) | 1/53 (2%) | 0 (0%) | 3/291 | 24 |
| Antinuclear antibody | 158/169 (94%) | 197/203 (97%) | 25/49 (47%) | 18 (13%) | 240/387 | 9 |
| Anti-PM-Scl antibody | NA | NA | NA | NA | NA | NA |
| Anti-RNA polymerase III antibody | NA | NA | NA | NA | NA | NA |
| Calcinosis | 10/56 (18%) | NA | 5/53 (9%) | 0 (0%) | 5/188 | 8 |
| Reduced DLCOb | 55/93 (59%) | NA | 12/38 (32%) | NA | 12/38 | 3 |
| Digital pulp loss or acro-osteolysis | 21/48 (25%) | NA | NA | NA | NA | NA |
| Dysphagia for solids | NA | NA | 17/53 (32%) | NA | 17/53 | NA |
| Esophageal dilation | NA | NA | NA | NA | NA | NA |
| Finger flexion contractures | 23/123 (19%) | NA | NA | NA | NA | NA |
| Finger tip ulcers or pitting scars | 77/173 (45%) | NA | 6/53 (11%) | 3 (2%) | 9/188 | 16 |
| Reduced FVCc | 24/95 (25%) | NA | 20/44 (46%) | NA | 20/44 | 0.4 |
| Interstitial lung disease or pulmonary fibrosis | 49/173 (28%) | 7/54 (13%) | 18/48 (38%) | 1/135 (1%) | 26/237 | 3 |
| Gastro-esophageal reflux disease | 115/174 (66%) | NA | 16/52 (31%) | 5 (4%) | 21/187 | 15 |
| Puffy fingers | 73/124 (59%) | NA | NA | 9 (7%) | 9/135 | 20 |
| Pulmonary arterial hypertension | 36/170 (21%) | 3/223 (2%) | 2/52 (4%) | NA | 5/275 | 14 |
| Raynaud phenomenon | 168/174 (97%) | 30/60 (50%) | 14/52 (27%) | 135 (100%) | 179/247 | 14 |
| Renal crisis | 13/174 (8%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 | NE |
| Scleroderma skin changes | 154 (88%) | 2/200 (1%) | NA | 4 (3%) | 6/335 | 402 |
| Telangiectasias | 31/65 (48%) | NA | NA | NA | NA | NA |
| Tendon or bursal friction rubs | NA | NA | NA | NA | NA | NA |
NA Not available, SLE Systemic lupus erythematosus, OR Odds ratio, NE Not Estimated
Notes:
a
Patients with inflammatory myopathy fulfilling criteria of Bohan and Peter, excluding those with overlap myopathy with systemic sclerosis or SLE
b
DLCO Carbon monoxide diffusion capacity, DLCO < 70% predicted
c
FVC Forced vital capacity; FVC < 70% predicted